EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
| 12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|
| Net operating profit after taxes (NOPAT)1 | ||||||
| Cost of capital2 | ||||||
| Invested capital3 | ||||||
| Economic profit4 | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
The period under review demonstrates fluctuating financial performance as measured by economic profit. Net operating profit after taxes (NOPAT) initially decreased from 2020 to 2021, then recovered in 2022, before declining again in 2023 and experiencing a substantial loss in 2024. Invested capital generally increased from 2020 to 2022, plateaued, and then decreased significantly in 2024. The cost of capital remained relatively stable throughout the period, with minor fluctuations.
- Economic Profit Trend
- Economic profit exhibited a positive trend from 2020 to 2022, peaking at approximately US$1.71 billion in 2022. This indicates the company generated returns exceeding its cost of capital during these years. However, economic profit decreased in 2023 and turned sharply negative in 2024, reaching a loss of approximately US$2.14 billion. This suggests that in 2024, the company’s returns were insufficient to cover its cost of capital.
- NOPAT and Invested Capital Relationship
- From 2020 to 2021, the decrease in NOPAT was partially offset by an increase in invested capital, resulting in a smaller decline in economic profit. The increase in both NOPAT and invested capital from 2021 to 2022 contributed to the peak in economic profit observed in 2022. The subsequent decline in NOPAT in 2023, coupled with a relatively stable invested capital base, led to a decrease in economic profit. The substantial decrease in NOPAT and the decrease in invested capital in 2024 resulted in a significant negative economic profit.
- Cost of Capital Stability
- The cost of capital remained consistently around 9.6% throughout the period. This stability suggests that the company’s risk profile, as perceived by investors, did not undergo significant changes. The consistent cost of capital highlights that the fluctuations in economic profit are primarily driven by changes in NOPAT and invested capital, rather than changes in the required rate of return.
The substantial shift to a negative economic profit in 2024 warrants further investigation to understand the underlying causes of the decline in NOPAT and the reduction in invested capital. The previous positive trend suggests the company possesses the capacity to generate economic profit, but recent performance indicates a need for strategic adjustments.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in equity equivalents to net income (loss).
3 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
4 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
5 Addition of after taxes interest expense to net income (loss).
6 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =
7 Elimination of after taxes investment income.
- Net Income (Loss)
-
The net income displayed an initial fluctuation with a decline from approximately 2.71 billion US dollars in 2020 to 2.34 billion US dollars in 2021. This was followed by a notable recovery reaching about 3.32 billion US dollars in 2022 and a further increase to approximately 3.62 billion US dollars in 2023. However, there was a significant reversal in 2024, with net income turning negative, resulting in a loss of approximately 536 million US dollars. This indicates a considerable downturn or an extraordinary expense impacting profitability in 2024.
- Net Operating Profit After Taxes (NOPAT)
-
The NOPAT value exhibited a similar pattern to net income but with some differences in magnitude and trend continuation. It started at around 3.02 billion US dollars in 2020 but dropped substantially to about 2.24 billion US dollars in 2021. There was a recovery in 2022 to nearly 3 billion US dollars; however, unlike net income that increased in 2023, NOPAT decreased to approximately 2.64 billion US dollars. In 2024, the NOPAT also turned negative, with a loss of about 1.27 billion US dollars, representing an even more pronounced operational challenge than indicated by net income alone.
- Summary of Trends and Insights
-
Both profitability measures show volatility over the five-year period with initial declines, strong recoveries, and significant downturns at the end of the period. The negative figures in 2024 for both net income and NOPAT highlight a substantial deterioration in performance. The larger negative NOPAT compared to net income in 2024 suggests a more severe erosion of operational efficiency or higher operating costs that may not be fully captured in net income calculations. These trends warrant further investigation into underlying causes such as market conditions, cost management, one-time charges, or other financial events impacting the company's profitability in the latest period.
Cash Operating Taxes
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Provision for income taxes
- The provision for income taxes displayed fluctuations over the observed period. It decreased from 405,151 thousand US dollars in 2020 to 388,300 thousand US dollars in 2021, indicating a slight reduction. However, in 2022, there was a significant increase to 910,400 thousand US dollars. Following this peak, the provision decreased somewhat in 2023 to 760,200 thousand US dollars and then showed a moderate increase again in 2024, reaching 784,100 thousand US dollars. Overall, the trend indicates heightened income tax provisions after 2021, with some volatility but maintaining higher levels than in the initial years.
- Cash operating taxes
- Cash operating taxes exhibited a strong upward trend from 2020 through 2023. Starting at 137,080 thousand US dollars in 2020, the cash taxes increased substantially to 556,675 thousand in 2021. This upward trajectory continued sharply into 2022, nearly doubling to 1,170,431 thousand US dollars. The peak was maintained in 2023 with 1,178,814 thousand US dollars, indicating stable but very high cash tax payments during that year. In 2024, cash operating taxes decreased to 1,029,919 thousand US dollars, showing a notable decline but remaining considerably elevated compared to 2020 and 2021.
- Comparative Insights
- Both provision for income taxes and cash operating taxes increased considerably after 2021, with cash operating taxes showing a more pronounced and consistent rise through 2023. The provision for income taxes experienced a sharp spike in 2022, followed by some reduction but remaining high through 2024. Cash operating taxes, while declining in 2024, stayed substantially higher than earlier years. This pattern could indicate changes in taxable income, tax planning strategies, or tax rate adjustments, resulting in elevated tax-related expenses and payments in recent years.
Invested Capital
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of equity equivalents to shareholders’ equity.
4 Removal of accumulated other comprehensive income.
5 Subtraction of marketable securities.
- Total Reported Debt & Leases
- The total reported debt and leases experienced a general decline from 2020 through 2023, decreasing from 942,460 thousand US dollars to 808,400 thousand US dollars. However, in 2024, there was a significant increase to 1,749,500 thousand US dollars, more than doubling the previous year's figure. This suggests a notable rise in leverage or financing activities in the most recent year.
- Shareholders’ Equity
- Shareholders' equity demonstrated a consistent upward trend from 2020 to 2023, increasing from 8,686,815 thousand US dollars to 17,580,400 thousand US dollars. This growth reflects an accumulation of retained earnings or capital injections over the years. In 2024, there was a slight decline to 16,409,600 thousand US dollars, indicating a minor reduction in equity, which may reflect distributions to shareholders, losses, or other equity adjustments.
- Invested Capital
- Invested capital rose steadily from 8,144,266 thousand US dollars in 2020 to 13,278,000 thousand US dollars in 2022. A plateau occurred between 2022 and 2023 with a marginal increase to 13,244,000 thousand US dollars. This was followed by a substantial decrease in 2024 to 9,046,000 thousand US dollars. This pattern may indicate a reduction in operating assets or a strategic realignment of capital deployment in the most recent period.
Cost of Capital
Vertex Pharmaceuticals Inc., cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2020-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| Economic spread ratio3 | ||||||
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The economic spread ratio demonstrates a declining trend over the observed five-year period. Initially strong, the ratio experienced a substantial decrease, culminating in a negative value in the most recent year. This shift is closely linked to changes in both economic profit and invested capital.
- Economic Spread Ratio Trend
- The economic spread ratio began at 27.48% in 2020, indicating a significant spread between the company’s return on invested capital and its cost of capital. This ratio decreased to 14.20% in 2021, suggesting a narrowing of this spread. The decline continued, with the ratio reaching 12.99% in 2022 and further decreasing to 10.24% in 2023. A marked shift occurred in 2024, with the ratio falling to -23.70%, signifying that the cost of capital exceeded the return generated from invested capital.
- Relationship to Economic Profit
- Economic profit generally decreased from 2020 to 2021, increased in 2022, decreased again in 2023, and then experienced a substantial decline into negative territory in 2024. This pattern directly influences the economic spread ratio, as the ratio is calculated based on economic profit and invested capital. The negative economic profit in 2024 is the primary driver of the negative economic spread ratio observed in that year.
- Relationship to Invested Capital
- Invested capital increased from 2020 to 2022, peaking at 13,178,000 US$ in thousands. It remained relatively stable between 2022 and 2023, then decreased significantly in 2024 to 9,046,000 US$ in thousands. While increases in invested capital without corresponding increases in economic profit would naturally compress the economic spread ratio, the substantial decrease in invested capital in 2024 was insufficient to offset the significant decline in economic profit, resulting in the negative ratio.
The observed trend suggests a weakening ability to generate returns exceeding the cost of capital. The negative economic spread ratio in 2024 warrants further investigation to understand the underlying causes and potential implications for future performance.
Economic Profit Margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Revenues | ||||||
| Performance Ratio | ||||||
| Economic profit margin2 | ||||||
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenues
= 100 × ÷ =
3 Click competitor name to see calculations.
The economic profit margin demonstrates a fluctuating performance over the five-year period. Initially strong, the margin experienced a decline before ultimately becoming negative.
- Economic Profit Margin Trend
- In 2020, the economic profit margin stood at 36.06%. This represents a substantial level of economic profit generation relative to revenue. A significant decrease was observed in 2021, with the margin falling to 17.60%.
- The margin partially recovered in 2022, reaching 19.17%, indicating some improvement in economic profit generation. However, this improvement was not sustained, as the margin decreased again in 2023 to 13.74%.
- A substantial shift occurred in 2024, with the economic profit margin declining to -19.46%. This indicates that the company’s economic losses exceeded its economic profits, resulting in a negative margin.
The trend in economic profit margin mirrors the trend in economic profit, though expressed as a percentage of revenue. The initial decline in economic profit in 2021 directly contributed to the decrease in the economic profit margin. While economic profit saw a partial recovery in 2022, it was insufficient to restore the margin to its 2020 level. The significant negative economic profit in 2024 drove the margin into negative territory.
- Revenue Relationship
- Revenues consistently increased throughout the period, moving from US$6,205,683 thousand in 2020 to US$11,020,100 thousand in 2024. Despite this revenue growth, the economic profit margin decreased overall, particularly in the final year, suggesting that revenue increases were not sufficient to offset increasing costs or decreasing profitability.
The negative economic profit margin in 2024 warrants further investigation to understand the underlying factors contributing to the economic loss. A detailed analysis of cost structures, capital allocation, and revenue generation strategies would be necessary to address this concerning trend.